J. Goldman & CO LP Leap Therapeutics, Inc. Transaction History

J. Goldman & CO LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.96 - $1.91 $155,520 - $309,420	-162,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.6 - $3.35 $604,800 - $1.27 Million	-378,000 Reduced 70.0%	162,000 $284,000
Q4 2021 Feb 14, 2022	BUY	$2.08 - $3.65 $1.12 Million - $1.97 Million	540,000 New	540,000 $1.75 Million
Q4 2020 Feb 16, 2021	SELL	$1.49 - $2.37 $1.17 Million - $1.87 Million	-787,326 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$1.68 - $2.17 $388,011 - $501,181	-230,959 Reduced 22.68%	787,326 $1.56 Million
Q2 2020 Aug 14, 2020	BUY	$1.39 - $2.84 $1.42 Million - $2.89 Million	1,018,285 New	1,018,285 $2.13 Million

265K

Ticker LPTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,021,400
Market Cap $288M
Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate can...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.